RHO and melanoma: We found that approximately half of the resistant human cutaneous melanomas have increased activation of the Rho/MRTF and/or YAP/TAZ pathway and that these mechanisms appear to play an important role in resistance to targeted therapy in this subset of melanomas (Misek et al., 2020; Foda and Neubig, 2023).